José Germán Sánchez Hernández-rekin lankidetzan egindako argitalpenak (8)

2022

  1. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 222-227

  2. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients

    European Journal of Pharmaceutical Sciences, Vol. 168

2021

  1. Comparison of ultra-performance liquid chromatography and ARK immunoassay for therapeutic drug monitoring of voriconazole

    Annals of Clinical Biochemistry, Vol. 58, Núm. 6, pp. 657-660

2020

  1. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1165-1175

  2. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease

    European Journal of Pharmaceutical Sciences, Vol. 150

2019

  1. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases

    Annals of Clinical Biochemistry, Vol. 56, Núm. 1, pp. 28-41

2018

  1. Diseño de un modelo poblacional para la monitorización farmacocinética de infliximab en enfermedad inflamatoria intestinal

    Farmajournal, Vol. 3, Núm. 1, pp. 77-85

2017

  1. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia

    Expert Review of Clinical Pharmacology, Vol. 10, Núm. 8, pp. 911-917